| (Values in U.S. Thousands) | Jul, 2026 | Jul, 2026 | Jul, 2026 | Jul, 2026 | Jul, 2026 |
| Sales | 0 | 0 | 0 | 0 | 0 |
| Sales Growth | unch | unch | unch | unch | unch |
| Net Income | 0 | 0 | 0 | 0 | 0 |
| Net Income Growth | unch | unch | unch | unch | unch |
Angiogenex Inc (AGGX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
AngioGenex, Inc. was incorporated in the State of Nevada on April 2, 1999. It is a biopharmaceutical company, focuses on the development of products that are used in the treatment, diagnosis, and prognosis of cancer. The company primarily engages in the research to develop anti-cancer strategies using the field of antiangiogenesis. The company's development programs focus on the discovery and development of orally active anti-cancer drugs that act by modulating the action of the Id (inhibitor of differentiation) proteins; the measurement of Id proteins in tumors and blood to create products for the diagnosis and prognosis of cancer; generating proof-of-concept data in relevant preclinical models to establish that modulation of Id genes and proteins is useful to treat non-oncologic diseases; and collaborating in respect to treatments of diseases in which blood vessel proliferation is desirable. The company has a worldwide license for two patent applications relating to a method for modulating tumor growth and metastasis of tumor cells based on the Id technology and Id knockout mice useful for testing and developing useful products for the treatment, diagnosis, and prognosis of cancer from the Memorial Sloan Kettering Cancer Center.